An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease.

@article{Lomas2012AnOI,
  title={An oral inhibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease.},
  author={David A. Lomas and David A Lipson and Bruce E. Miller and Lisa R Willits and Oliver N. Keene and Helen Barnacle and Neil C. Barnes and Ruth Tal-Singer},
  journal={Journal of clinical pharmacology},
  year={2012},
  volume={52 3},
  pages={416-24}
}
The aims were to determine the effect of an oral inhibitor of the signaling mediator p38 mitogen-activated protein kinase (GW856553, losmapimod) on sputum neutrophils, pulmonary function, and blood biomarkers of inflammation in chronic obstructive pulmonary disease (COPD). Three hundred and two individuals with GOLD stage II COPD were randomized to oral losmapimod 7.5 mg twice daily, inhaled salmeterol/fluticasone propionate 50 µg/500 µg combination (SFC), or placebo in a 12-week, randomized… CONTINUE READING
43 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 43 extracted citations

Similar Papers

Loading similar papers…